A tetanus-diphtheria shot that sat at 30C for a year worked. Now the paperwork is the bottleneck.

An experimental tetanus-diphtheria combination vaccine stored at up to 30 degrees Celsius for a year produced antitoxin immunity matching that of two conventional comparators in a 60-person UK trial, reported August 5 in Lancet Discovery Science ^{[1][2][9][10]}. If the result holds in larger trials, the limiting factor on reaching unvaccinated populations stops being refrigeration capital and becomes the regulatory language on the label.

The scale of the current problem is not subtle. Agencies including the U.S. Centers for Disease Control and Prevention recommend holding vaccines between 2C and 8C from manufacture to administration ^[5]. About 2.7 billion people lack reliable access to vaccines, in some cases because cold storage equipment has been destroyed or fuel and power supplies fail ^[6]. Half of all vaccine doses produced globally each year are wasted, largely because storage temperatures move outside that window ^[4].

The World Health Organization already grants exceptions where heat does not affect stability, but those typically cover only 3 to 4 days outside refrigeration ^[7]. A year at 30C is roughly 90 to 120 times longer than that allowance ^[1]. Freeze-dried products can do better, and a freeze-dried oral rotavirus vaccine keeps at 25C for 30 months, but the source describes that as a rare example, and the low temperatures in freeze-drying can themselves damage vaccine components ^[8].

The work came out of the National Institute for Health and Care Research in England, where pediatric immunologist Saul Faust's group started from TetaDif, an existing tetanus-diphtheria combination ^[11]. Their partner, London-based Stablepharma, uses a process called StablevaX that mixes inert pharmaceuticals, including the sugar trehalose, into the antigen before freeze-drying; the additives form a layer that immobilizes the components as temperatures rise ^[12]. The inspiration was desert plants that substitute trehalose for water to hold cell shape through drought ^[13]. The dose is reconstituted with sterile water before injection, which means the last mile trades a refrigerator for sterile water and a mixing step at the point of care ^[14].

In the trial, 60 UK participants aged 18 to 55 who had not had a tetanus or diphtheria vaccine in at least 10 years received one dose of the new product, SPVX02, or TetaDif, or another combination called diTeBooster ^[9]. SPVX02 caused no serious side effects, and at 28 days all recipients had immunity to both toxins matching the comparator groups ^[10]. In animal studies the vaccine held potency at 30C and 75 percent humidity for two years, and at 40C and 75 percent humidity for six months ^[15].

Karen O'Hanlon, Stablepharma's chief operating officer, says the data show efficacy equal to existing vaccines and that the company can confidently extend fridge-free shelf life to at least four years, which she calls significantly longer than any other vaccine product currently on the market ^[16][17]. That is a developer's claim about its own product, and four years is not what was tested in humans. Jennifer Pancorbo, a chemical engineer at North Carolina State University, said she was pleased to see a possible route around the limitations of freeze-drying and an immune response equal to or better than standard vaccines ^[18].

Three things to watch. A larger trial will compare SPVX02 with TetaDif in 160 people ^[19]. The team is testing whether the same technique works for hepatitis B and HPV, which would change procurement math far more than a Td booster does ^[3]. And regulators would need a label category for year-scale ambient storage, because the existing exception tops out at days ^[7].